Table 4.

Hemodynamic measurements before (baseline) and 5 min after the start of angiotensin II infusion in Ndufs4^−/− and Ndufs4^+/+ mice breathing air

				HR, beats/min		MAP, mmHg		PAP, mmHg		QLPA, µl⋅min−1⋅g−1		LPVRI, mmHg⋅min⋅g⋅ml−1
Genotype	Treatment		n	Baseline	ANG II	Baseline	ANG II	Baseline	ANG II	Baseline	ANG II	Baseline	ANG II
Ndufs4+/+	ANG II (0.5 µg·kg−1·min−1)		5	542 ± 36	620 ± 23a	82 ± 8	134 ± 5a	18 ± 1	26 ± 2a	88 ± 6	67 ± 6a	88 ± 5	216 ± 12a
Ndufs4−/−	ANG II (0.5 µg·kg−1·min−1)		4	506 ± 23	617 ± 9a	74 ± 5	138 ± 8a	19 ± 2	29 ± 3a	104 ± 17	61 ± 9a	107 ± 23	259 ± 57a

Values are means ± SE. Group differences were compared by Student’s t-test. The effect of angiotensin II (ANG II) on each parameter was analyzed in each group by a paired Student’s t-test. HR, heart rate; LPVRI, left pulmonary vascular resistance index; MAP, mean arterial pressure; PAP, pulmonary arterial pressure; Q_LPA, left pulmonary arterial blood flow.

^aP < 0.05 vs. baseline value of the same parameter in the same treatment group.